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34613
Tapinarof cream 1% once daily (QD) for plaque psoriasis:
Secondary efficacy outcomes from a long-term extension (LTE)
trial
Linda Stein Gold, MD, Henry Ford Health System, Detroit, MI; Benjamin
Ehst, MD, PhD, Oregon Medical Research Center, Portland, OR; Laura K. Ferris,
MD, PhD, UPMC Department of Dermatology, Pittsburgh, PA; Philip M. Brown,
MD, JD, Dermavant Sciences, Morrisville, NC; David S. Rubenstein, MD, PhD,
Dermavant Sciences, Morrisville, NC; Anna M. Tallman, PharmD, Dermavant
Sciences, Morrisville, NC; Jerry Bagel, MD, MS, Psoriasis Treatment Center of
New Jersey, East Windsor, NJ
Background: Tapinarof cream 1% QD was efficacious and well tolerated versus
vehicle in adults with mild-to-severe plaque psoriasis in 2 double-blind 12-week
Phase 3 trials (PSOARING 1&2). We report secondary efficacy from PSOARING 3,
the LTE trial assessing tapinarof during intermittent treatment based on Physician
Global Assessment (PGA) score.
Methods: Eligible PSOARING 1&2 completers could enroll for 40-weeks’ open-label
tapinarof 1% QD and 4-weeks’ follow-up in PSOARING 3. Patients entering with PGA
$1 were treated until PGA ¼ 0. Patients entering with/achieving PGA ¼
0 discontinued tapinarof until PGA $2, then retreated until PGA ¼ 0.
Results: 91.6% (n ¼ 763) eligible patients enrolled in PSOARING 3. Efficacy
improved beyond 12-week pivotal trials and was maintained over time. In
PSOARING 1&2, overall mean baseline body surface area (BSA) affected was
7.6e7.9% and Psoriasis Area Severity Index (PASI) was 8.87e9.12. PSOARING 3
baseline mean BSA affected was 4.7% (3.3% and 7.3% previously treated with
tapinarof and vehicle, respectively) and mean PASI was 4.76 (3.28 and 7.69 tapinarof
and vehicle, respectively). At week 40, significant improvements beyond pivotal
trials were observed: overall mean improvement from baseline in BSA affected was
e2.0%; PASI75 and PASI90 responses were 29.4% and 17.5%, respectively (beyond
the PASI75 of 36.1% and 47.6%; PASI90 of 18.8% and 20.9% in PSOARING 1&2,
respectively). No new safety signals were observed.
Conclusion: Continued improvements beyond 12 weeks and durable responses/no
tachyphylaxis were observed across secondary efficacy outcomes which, together
with previously reported high rates of complete disease clearance (PGA ¼ 0) and
;4-month remittive effect off-therapy, differentiate tapinarof from other topical
therapies.
Commercial Disclosure: 100% is sponsored by Dermavant Sciences, Inc.
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Tapinarof cream 1% once daily for plaque psoriasis: Dermatology Life Quality Index and local tolerability scores from a
long-term extension trial
April W. Armstrong, MD, MPH, Keck School of Medicine University of
Southern California, Los Angeles, CA; Seemal R. Desai, MD, Department of
Dermatology, The University of Texas Southwestern Medical Center, Dallas, TX
Innovative Dermatology, Plano, TX; Melinda Gooderham, MSc, MD, FRCPC, SKiN
Centre for Dermatology, Peterborough, Ontario, Canada; David S. Rubenstein,
MD, PhD, Dermavant Sciences, Morrisville, NC; Philip M. Brown, MD, JD,
Dermavant Sciences, Morrisville, NC; Anna M. Tallman, PharmD, Dermavant
Sciences, Morrisville, NC; Leon Kircik, MD, Skin Sciences, PLLC Louisville, KY
Background: We present Dermatology Life Quality Index (DLQI) and local
tolerability scores of tapinarof cream 1% once daily during repeated, intermittent
treatment for plaque psoriasis in PSOARING 3 (n ¼ 763), the long-term extension
trial of two 12-week, double-blinded, vehicle-controlled Phase 3 trials (PSOARING
1&2).
Methods: Eligible PSOARING 1&2 completers could enroll for 40-weeks’ open-label
treatment and 4-weeks’ follow-up in PSOARING 3. Patients entering with Physician
Global Assessment (PGA) score $1 received tapinarof until complete disease
clearance (PGA ¼ 0). Patients with PGA ¼ 0 discontinued tapinarof. Clear patients
who then developed PGA$2 were retreated until PGA ¼ 0. DLQI (range 0e30,
lower ¼ better quality-of-life), patient- and investigator-reported local tolerability
were assessed (range 0e4, lower ¼ better tolerability).

33152
Targeted combined endpoint improvement in patient and disease domains in atopic dermatitis (AD) among adults with
moderate-to-severe AD treated with upadacitinib
Shawn G. Kwatra, MD, Department of Dermatology, Johns Hopkins
University School of Medicine, Baltimore, MD; Marjolein De Bruin-Weller, MD,
PhD, University Medical Center Utrecht, Utrecht, Netherlands; Peter Lio, MD,
Feinberg School of Medicine, Northwestern University, Chicago, IL; Mette
Deleuran, MD, MDSc, Department of Dermatology, Aarhus University Hospital,
Aarhus, Denmark; Sarah Ofori, PharmD, RPh, MBA, AbbVie Inc., North Chicago,
IL; Henrique D. Teixeira, PhD, MBA, AbbVie Inc., North Chicago, IL; Brian
Calimlim, DRPH, MS, AbbVie Inc., North Chicago, IL; Yingyi Liu, PhD, AbbVie
Inc., North Chicago, IL; Stephen Weidinger, MD, Department of Dermatology and
Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
Recommendations for a treat-to-target approach were recently developed to guide
systemic therapy for disease control in adults with AD. Recommendations outlined
criteria for a 3-month initial acceptable target goal: reduction from baseline $1 on a
5-level Patient Global Impression of Severity (PGIS) scale and $1 specific disease
domain target ($50% improvement from baseline in Eczema Area and Severity Index
[EASI-50]; $50% reduction in Scoring of AD [SCORAD-50]; and a reduction from
baseline in Worst Pruritus Numerical Rating Scale [WP-NRS] $3, Dermatology Life
Quality Index [DLQI] $4, or Patient Oriented Eczema Measure [POEM] $4); and a 6month optimal target goal: PGIS #2 and $1 specific disease domain target (EASI-75
or EASI #7, SCORAD-75 or SCORAD #24, WP-NRS #4, DLQI #5, POEM #7).
Achievement of these criteria with once-daily upadacitinib (15 mg and 30 mg)
monotherapy was compared with placebo using integrated adult data from MU1 and
MU2 trials and nonresponder imputation incorporating multiple imputation for
missing values due to COVID-19. Greater proportions of patients treated with
upadacitinib 15 mgj30 mg vs placebo (P\.001 for all) achieved the initial acceptable
target goal at week 2 (78.9%j82.6% vs 25.0%) and week 16 (72.5%j80.2% vs 22.9%),
and the optimal target goal at week 2 (52.8%j64.3% vs 6.3%) and week 16 (56.2%j
70.1% vs 13.9%). These results suggest that once-daily oral upadacitinib (15 mg and
30 mg) may help improve standards of care in patients with moderate-to-severe AD
by achieving 6-month target goals at 16 weeks and as early as 2 weeks for most
patients.
Commercial Disclosure: SGK has served as an investigator and/or adviser to
AbbVie, Celldex Therapeutics, Galderma, Incyte, Kiniksa Pharmaceuticals,
Novartis, Pfizer, Regeneron Pharmaceuticals, and Sanofi. MDB-W is a principal
investigator, advisory board member, and consultant.
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Testing clinical efficacy of exfoliants against pollution and photoaging for healthy skin maintenance
Nalini Kaul, MSc, PhD, Princeton Cosumer Corp, Elsie Kohoot,
Princeton Consumer Research, Barrie Drewitt, Princeton Consumer
Research

Conclusions: Tapinarof cream showed continued and durable improvement in
quality of life and was well tolerated with long-term use, as reported by patients and
investigators, irrespective of intermittent treatment during PSOARING 3. Together
with previously reported efficacy and safety, including a high rate of disease
clearance (PGA ¼ 0), ;4-month remittive effect, and no tachyphylaxis, these
findings differentiate tapinarof cream from other topical therapies for psoriasis.

Photoaging/environmental aging causes damage and wrecks human skin over the
course of a life span. With pollutants, particulate matter, and photoaging, photodamage is superimposed on changes occurring with intrinsic aging. Clinical
characteristics of cutaneous photoaging include fine lines, wrinkles, roughness,
dullness, laxity, mottled pigmentation, and age spots/hyperpigmentation. The skin
needs additional supportive care besides photoprotection with sunscreen and with
antioxidants. Addition of plant exfoliants is becoming increasingly popular in
keeping skin clean by breaking down the accumulation of particulate matter,
removing dead cells/debris from the epidermis, exposing new cells, unclogging
pores, and helping with age spots, brightening. and blurring lines. Plant-based
superficial peel exfoliants like alpha and beta hydroxy acid or enzymes like papain
and bromelain or retinol star - bakuchiol are increasingly gaining popularity because
they are affordable and convenient with freedom of self-use. Our objective was to
test the efficacy of exfoliants on various antiaging attributes in a 4-week clinical
design on 70 healthy volunteers (F-35-65 y). Assessments include lines, wrinkles,
roughness, skin tone, pores, and hyperpigmentation by a trained grader, antipollution assessment with particulate matter, brightness with colorimeter, elasticity,
firmness with cutometer, analysis of digital photographs taken with VISIAR CR along
with volunteer self-perception. Our results showed product efficacy with exfoliation introduced antiaging skin modifications in terms of antipollution, skin
brightness, softness, tightness, pore size, hyperpigmentation, and age spots. In
conclusion, topical plant-based exfoliants enriched with other natural ingredients
help remove pollutants, dead cells, reduce blemishes, discoloration, wrinkles
besides stimulating cell growth, and thus are integral to healthy skin maintenance.

Commercial Disclosure: 100% is sponsored by Dermavant Sciences, Inc.
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Results: Mean baseline DLQI scores in PSOARING 1&2 were 8.2e8.7. At baseline in
PSOARING 3, mean DLQI was 4.3 overall (3.3 and 6.2 if previously treated with
tapinarof or vehicle, respectively). DLQI scores continued to improve and were
maintained over time. At week 40, mean DLQI was 1.8 overall. Tapinarof was well
tolerated with long-term use, with mean overall patient-reported local tolerability of
0.93 (none-to-slight irritation) and investigator-assessed irritation of 0.07 (no
irritation) at week 40.
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